New Mazdutide Publication in Diabetes, Obesity & Metabolism

A new publication on mazdutide appeared on October 14, 2026, in the journal Diabetes, Obesity & Metabolism. The paper is titled "The GLP-1R/GCGR Dual Agonist Mazdutide Attenuates Liver Steatosis and Decreases Circulating Cholesterol Levels in Mice With Metabolic Dysfunction-Associated Steatotic Liver Disease." Mazdutide is described in the publication as a dual agonist of the GLP-1 receptor and the glucagon receptor. The study was conducted in a mouse model of metabolic dysfunction-associated steatotic liver disease, as indicated by the publication title. Mazdutide remains an unapproved compound under research investigation and is not currently approved for clinical use. This brief reports only the existence and title of the publication as listed in the source record. No specific findings, data, or outcome figures from the study are included here beyond what is stated in the title itself. Readers interested in the full details of the methodology and results should consult the original publication directly through the journal. For additional background on mazdutide, including its development history and regulatory status, readers can refer to the compound overview.